TH65585B - Anti- (formula) v (formula) 6 antibodies - Google Patents

Abstract

DC60 (22/05/46) Monoclonal antibodies that bind specifically to vbeta6 also include methods of using these antibodies to treat mammals with or at risk of having vbeta6-mediated diseases or to diagnose vbeta6-mediated diseases.

Claims (9)

Disclaimer (all) which will not appear on the advertisement page. : ------ 07/11/2017 ------ (OCR) Page 1 of 3 pages Disclaimer 1. 1. 1. 4. Isolated antibody or its antigen binding fraction. Where (i) catches specifically with (symbol) v (symbol) 6; (ii) competes with 6.8G6 (ATCC possession number PTA-3645) for catching (symbol) v (symbol) 6; And (iii) combined with FXY dominant traits in CDR 3 of the heavier strands, where the isolated antibody or its antigen-binding fraction inhibits the binding of (symbol) v (symbol) 6 to the peptide associated with the trait. Latent (LAP) 5. Antibodies specifically bound to (symbol) v (symbol) 6, where the humanized antibody (i) of the antibody produced by the 6.1A8 hybrid with ATCC number occupied. PTA-3647, Hybridma 6.3G9 with ATCC PTA-3649, Hybrid 6.8A6 with ATCC PTA-3645, Hybridma 6.2B1 with ATCC PTA-3646, Hi. The Bredoma 7.1G10 with the ATCC occupied PTA-3898, the Hybridma 7.7G5 with the ATCC occupying the PTA-3899, and the Hybridma 7.1C5 with the ATCC PTA-3900 and (ii) included. Residual mutations of amino acids, which are regions for glycosylation in Antibody produced by hybridoma selected from a group containing hybridoma 6.1A8, hybridma 6.3G9, hybridma 6.8G6, hybridma 6.2B1, hybrid. Bridoma 7.1G10, hybridoma 7.7G5, and hybridoma 7.1C5, as at the glycosylation region, were eliminated. 6. Antibodies of claim 5, wherein (i ) The human-like nature of the antibody produced by the 6.3G9 hybrid with ATCC possessed number PTA-3649 and (ii) combined with the remaining mutation of the amino acid area for distant Cosylation in The antibodies produced by the 6.3G9 hybrids as at the glycosylation region were eliminated on page 3 of the number 3, page 7. Antibodies of one of the claims 1-6. Match with cytotoxic, radioactive compound, or anticancer agent 8. Antibody of claim 1-6 where the antibody is mated to polyethylene glycol 9. Antibody of any of the 1-6 claims, wherein the antibody is paired with a fluorescent fraction 1 0. Preventive or therapeutic component passed by (symbol) v (symbol) 6 in humans where Includes an antibody of claim 1-8 and a pharmaceutical acceptable carrier 1 1. Element of claim No. 10, where disease is fibrosis 1 2. . Element of claim 10, where fibrosis is abnormal fibrosis 1 3. Element of claim 10, where disease is a type of lung injury. Severe 1 4. Elements of claim No. 10, where disease is cancer 1 5. Elements of claim No. 10. 14 where the cancer is mouth, skin, cervix, ovary, mollusk, throat, esophagus, lung, breast, kidney or coloreectal 1 6. In vitro methods of (Symbol) v (symbol) 6 In a human tissue sample, subjects at Combined by touching the tissue sample with the antibody of any of Clause 1 to 9 ------------ ------ 07/11/2017 ----- - (OCR) page 1 of number 3 pages. Claims 1. 1. 1. 4. Isolated antibody or its antigen binding part that (i) binds specifically to (symbol) v (symbol) 6; (ii) Compete with 6.8G6 (ATCC PTA-3645 Possession Number) for the Grip (Symbol) v (Symbol) 6; And (iii) combined with FXY dominant traits in CDR 3 of the heavier strands, where the isolated antibody or its antigen-binding fraction inhibits the binding of (symbol) v (symbol) 6 to the peptide associated with the trait. Latent (LAP) 5. Antibodies specifically bound to (symbol) v (symbol) 6, where the humanized antibody (i) of the antibody produced by the 6.1A8 hybrid with ATCC number occupied. PTA-3647, Hybridma 6.3G9 with ATCC PTA-3649, Hybrid 6.8A6 with ATCC PTA-3645, Hybridma 6.2B1 with ATCC PTA-3646, Hi. The Bredoma 7.1G10 with the ATCC occupied PTA-3898, the Hybridma 7.7G5 with the ATCC occupying the PTA-3899, and the Hybridma 7.1C5 with the ATCC PTA-3900 and (ii) included. Residual mutations of amino acids, which are regions for glycosylation in Antibody produced by hybridoma selected from a group containing hybridoma 6.1A8, hybridma 6.3G9, hybridma 6.8G6, hybridma 6.2B1, hybrid. Bridoma 7.1G10, hybridoma 7.7G5, and hybridoma 7.1C5, as at the glycosylation region, were eliminated. 6. Antibodies of claim 5, wherein (i ) The human-like nature of the antibody produced by the 6.3G9 hybrid with ATCC possessed number PTA-3649 and (ii) combined with the remaining mutation of the amino acid area for distant Cosylation in The antibodies produced by the 6.3G9 hybrids as at the glycosylation region were eliminated on page 3 of the number 3, page 7. Antibodies of one of the claims 1-6. Match with cytotoxic, radioactive compound, or anticancer agent 8. Antibody of claim 1-6 where the antibody is mated to polyethylene glycol 9. Antibody of any of the 1-6 claims, wherein the antibody is paired with a fluorescent fraction 1 0. Preventive or therapeutic component passed by (symbol) v (symbol) 6 in humans where Includes an antibody of claim 1-8 and a pharmaceutical acceptable carrier 1 1. Element of claim No. 10, where disease is fibrosis 1 2. . Element of claim 10, where fibrosis is abnormal fibrosis 1 3. Element of claim 10, where disease is a type of lung injury. Severe 1 4. Elements of claim No. 10, where disease is cancer 1 5. Elements of claim No. 10. 14 where the cancer is mouth, skin, cervix, ovary, mollusk, throat, esophagus, lung, breast, kidney or coloreectal 1 6. In vitro methods of (Symbol) v (symbol) 6 In a human tissue sample, subjects at It consists of touching the tissue sample with the antibodies of any of the 1st to 9th claims ------------ 1. Monoclonal antibodies which (a) bind exclusively to (Formula) v (formula) 6 and (b) inhibit the binding of (formula) v (formula) 6. Per peptide that It is associated with latent traits (LAP) with a lower IC50 value of 10D5 2. Antibodies of claim 1 where the antibodies are composed. With heavy polypeptide sequence And the same lighter line The antibody produced by the 6.1A8 hybrid (ATCC PTA-3647 possession number) 3. Antibody of claim 1 where the antibody is composed. With heavy polypeptide sequence And the same lighter line Antibody produced by the 6.3G9 hybrid (ATCC PTA-3649 possession number) 4. Antibody of claim 1 where the antibody is composed. With heavy polypeptide sequence And the same lighter line The antibody produced by the Hybridma 6.8G9 (ATCC PTA-3645 possession number) 5. Antibody of claim 1 where the antibody is composed. With heavy polypeptide sequence And the same lighter line Antibody produced by the 6.2B1 hybrid (ATCC PTA-3646 possession number) 6. Antibody of claim 1 where the antibody is composed. With heavy polypeptide sequence And the same lighter line Antibody produced by the 7.1G10 hybrid (ATCC PTA-3898 possession number) 7. Antibody of claim 1, whereby the antibody is composed. With heavy polypeptide sequence And the same lighter line Antibody produced by the 7.7G5 hybrid (ATCC PTA-3899 possession number) 8. Antibody of claim 1, wherein the antibody is composed. With heavy polypeptide sequence And the same lighter line Antibody produced by hybridoma 7.1C5 (ATCC PTA-3900 possession number) 9. Antibody of claim 1 whereby binding between the antibody and (Formula) v (Formula) 6 is dependent on the positive ion. Divalent cation-dependent 1 0. Antibody of claim 9 where the divalent cation-dependent is Ca2 +, Mg2 + or Mn2 + 1. 1. Antibody of claim 1 by capture. island Between the antibody and (formula) v (formula) 6, divalent cation-independent 1 1., 13 and 15 are not required, respectively, 1 1., 14 and 17 respectively 1 1., 14 and 18 respectively, 1 1., 13 and 16 respectively, 1 1., 57 and 59 respectively, 1 1., 58 and 60 respectively, 1 1.-36 and 61-62 1 1. 2 1. 2 1. 2 1. 2 1. 2 1. 2 1. 2 1. 2 1. 2 1. 2 1. 3 0. Monoclonal antibody Which seized the island specifically (Formula) v (formula) 6 But does not inhibit the capture of the island (Formula) v (formula) 6 Per peptide involved 3. Antibodies of claim 30, where the antibodies Contains heavy strand polypeptide sequences. And the same lighter line It is compatible with the antibody produced by the Hybridoma 6.2A1 (ATCC Cover Number PTA-3896) 3 2. Antibody of claim 30 where the antibodies Contains heavy strand polypeptide sequences. And the same lighter line It is compatible with the antibody produced by the 6.2E5 hybrid (ATCC cover number PTA-3897) 3 3. Mixture for prevention. Or therapy through an intermediate by (formula) v (formula) 6 In mammals containing antibodies Of any of Clause 1-32 and the Pharmaceutical Acceptable Carrier 3 4. Mixture for Prevention Or therapy through an intermediate by (formula) v (formula) 6 In mammals containing antibodies Of any of Clause 1-32 and a pharmaceutical acceptable carrier, where the antibody is conjugated with the cytotoxic 3 5. Mixture of claim 33, where the antibody are Ion-positive 3 antibodies 6. Use of claim 32 mixtures for the production of treatment of patients with or at risk of disease mediated by (Formula) v (formula) 6 to achieve a relief or shift. Initial stage of disease per patient 3 7. Use of claim 36 mixtures, where the patient is human 3 8. Use of claim 36 mixtures where disease is intervention. Create texture Fibrosis 3 9. The use of a mixture of claim 38 where the disease is tissue formation. Fibrosis (fibrosis) is a screodema, ulceration, abnormal production of liver tissue, abnormal renal fibrosis, or abnormal hyperpigmentation of the lungs. 4 0 Mixture use of claim 36, where the disease is psoriasis 4. 1. Use of the mixture of claim 36, where disease is cancer 4. 2. The use of a mixture of claim 41 where cancer is epithelial cancer 4. 3. The use of a mixture of claim 41 where cancer is mouth, skin, cervix, ovary, pharynx, throat, esophagus, lung, breast, kidney or coloreectal 4. 4. The use of a mixture of claim 36, where the disease is Alport \ 's Syndrome 4. 5. Method of detection (Formula) v (formula) 6 In animal tissue samples Mammals that consist of touching a sample of meat. Membranes with antibodies of claim 1 or 30 4. 6. Method of claim 45, whereby antibodies are selected. Comes from a group consisting of 6.2A1 (ATCC PTA 3896 Possession Number) and 6.2E5 (ATTC PTA 3897 Possession Number) 4. 7.Hybrid cell 6.1A8 (ATCC number PTA-3647) 4 8.Hybridoma cell 6.2B10 (ATCC number occupies PTA-3648) 4 9. Hybridma cell 6.3G9 (ATCC number occupies PTA-3649) 5 0.Hybridoma cell 6.8 G6 (ATCC PTA-3645) 5 1. Hybridma 6.2B1 cell (ATCC PTA-3646) 5 2. Hybridma 6.2A1 cell (ATCC PTA-3896) 5 3. Hybridma cell 6.2E5 (ATCC number occupies PTA-3897) 5 4. Hybridma cell 7.1G10 (ATCC number occupies PTA-3898) 5 5. Hybridma cell 7.7 G5 (ATCC PTA-3899) 5 6.-cell 7.1C5 hybrid (ATCC PTA-3900) 5 1.-45 and 61-64 5 1.-45 and 61-64 5 9. A monoclonal antibody containing a polypeptide sequence in Heavy and light lines The same with the antibody produced by the 6.2B10 hybrid (ATCC possession number PTA-3648).